Long-acting platform technology
Overview
Protein/peptide therapeutics should be administered frequently due to their short half-lives, causing inconvenience to patients.
We are focusing on improving therapeutic efficacy and patients’ quality of life by adopting various long-acting platform technologies that can be tailored for each individual biotherapeutics.
We are focusing on improving therapeutic efficacy and patients’ quality of life by adopting various long-acting platform technologies that can be tailored for each individual biotherapeutics.
- LAPSCOVERYTM
- Hanmi’s unique technology to prolong the duration of drug action using flexible linkers that connect aglycosylated Fc and therapeutic agents
- Fc fusion
- Long-acting technology that extends the duration of the therapeutic efficacy by fusing therapeutic drugs to the Fc fragment using recombination DNA technology
- Acylation
- Long-acting technology for therapeutic peptides using fatty acid which bind to human albumin to reduce renal clearance.